"We have clinically proven Stelara for Koreans"
By Moon, sung-ho | translator Hong, Ji Yeon
24.10.28 05:39:38
°¡³ª´Ù¶ó
0
"Appropriate for treating patients with terminal ileal Crohn's disease¡¦expands clinical treatment options"
Due to its wide variety of conditions, Crohn's disease requires customized long-term treatment depending on the disease type and inflammatory region. When treating patients with Crohn's disease, the location of the disease is challenging because the intestinal tract of the ileum (lower part of the small intestine) is narrow.
Recently, the research results of the K-STAR study, the Real-World Evidence (RWE) study of Stelara, a drug containing the original ingredient ustekinumab, was conducted for the first time in Korean patients, were published in 'IBD (Inflammatory Bowel Diseases) Journal.' The K-STAR study followed the effects and safety of Stelara in Korean patients with Crohn's disease over a year.
Moon, sung-ho(lib6983@dailypharm.com)
If you want to see the full article, please JOIN US (click)